AffaMed Therapeutics Reports Positive Top-Line Results From Study Evaluating DEXTENZA
(RTTNews) - Biotechnology company AffaMed Therapeutics announced Tuesday positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.
The trial met its primary endpoint, with Dextenza demonstrating a significant reduction of ocular inflammation as measured by the absence of anterior chamber cells in the study eye on Day 14 after cataract surgery.
The trial also met its secondary endpoint, demonstrating a significant reduction of ocular pain on Day 8.
Dextenza was also well-tolerated and had a favorable safety profile consistent with all prior trials.
In October 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix, Inc. (OCUL) for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets.
DEXTENZA is approved in the U.S. and MacauSAR for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.
U.S. Consumer Confidence Edges Modestly Lower In October
PayPal Lifts FY25 Outlook Above Market, Teams With OpenAI; Stock Up
Falling Commodity Prices Likely To Weigh On Canadian Market At Open
German GfK Consumer Sentiment To Continue Falling On Weak Income Expectations
UPS Sees Q4 Revenues Above Street As Q3 Beats Market, Despite A Fall; Stock Gains
FTSE 100 Flat; HSBC Holdings, Airtel Africa Rise After Results
CAC 40 Down Slightly; Earnings In Focus
